Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saracatinib + carboplatin
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy of **saracatinib (AZD0530)**, a potent, selective, orally available Src and Abl kinase inhibitor, and **carboplatin**, a platinum-based chemotherapeutic cytotoxic agent. Saracatinib targets non-receptor tyrosine kinase c-Src and Bcr-Abl, blocking pathways involved in tumor cell migration, invasion, and potentially chemoresistance, while carboplatin crosslinks DNA to cause cell death in rapidly dividing tumor cells. The combination has been studied primarily in advanced solid tumors, especially ovarian cancer, in both preclinical and clinical (phase I/II) settings, aiming to improve efficacy and circumvent resistance to platinum-based chemotherapy. The combination shows acceptable toxicity and feasibility in early-phase clinical trials, but no evidence for regulatory approval to date[1][2][3][4][5][6][7].
- Other names
- AZD0530 + carboplatinsaracatinib + carboplatin
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)DNASRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on saracatinib + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saracatinib + carboplatin.